Standardizing the Response to Category II Tracings during Induction with Oxytocin: A Cost-Effectiveness Analysis

Louisa R. Chatroux, Leah M. Savitsky, Blake Zwerling, Justin Williams, Alison G. Cahill, Aaron Caughey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Oxytocin is one of the most frequently used medications in obstetrics. It is generally considered to be safe and effective for induction and augmentation of labor but has been implicated in uterine hyperstimulation and adverse fetal outcomes. The management of labor with oxytocin in response to changes in fetal status remains an area of debate. Objective This study sought to assess the cost-effectiveness of reducing or ceasing oxytocin administration in response to Category II fetal heart rate tracings. Study Design A decision-analytic model was built using TreeAge 2016 software (TreeAge Software Inc.) with probabilities, costs, and utilities derived from the literature. Primary outcomes included cerebral palsy (CP), neonatal mortality, and mode of delivery. Secondary outcomes included cost per quality-adjusted life year (QALY; cost-effectiveness threshold set at $100,000/QALY), admission to the neonatal intensive care unit (NICU), and low 5-minute Apgar score (<7). Sensitivity analyses were performed to determine the robustness of our baseline assumptions. Results In a theoretical cohort of 900,000 women (estimated number of women undergoing induction at term in the United States), decreasing or stopping oxytocin in response to Category II tracings prevented 12,510 NICU admissions, 4,410 low Apgar scores, 204 neonatal deaths, and 126 cases of CP. However, there were 81,900 more cesarean deliveries. The strategy cost $356 million more, but was cost-effective with an ICER of $9,881.5 per QALY. Sensitivity analysis revealed that the intervention would be cost-effective up to a cesarean rate of 54%. Conclusion Decreasing or stopping oxytocin in response to Category II fetal heart rate tracings is cost-effective. This intervention increases the rate of cesarean deliveries but reduces neonatal morbidity and mortality. Further work on this guideline should be performed to ascertain how the approach using different aspects of the Category II tracing to guide care might lead to similar improved outcomes without increasing the cesarean delivery rate.

Original languageEnglish (US)
JournalAmerican Journal of Perinatology
DOIs
StateAccepted/In press - Aug 16 2017

Fingerprint

Oxytocin
Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Fetal Heart Rate
Apgar Score
Neonatal Intensive Care Units
Infant Mortality
Cerebral Palsy
Software
Induced Labor
Obstetrics
Guidelines
Morbidity

Keywords

  • Category II tracing
  • cost-effectiveness
  • fetal heart rate monitoring
  • induction
  • labor management
  • oxytocin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Standardizing the Response to Category II Tracings during Induction with Oxytocin : A Cost-Effectiveness Analysis. / Chatroux, Louisa R.; Savitsky, Leah M.; Zwerling, Blake; Williams, Justin; Cahill, Alison G.; Caughey, Aaron.

In: American Journal of Perinatology, 16.08.2017.

Research output: Contribution to journalArticle

Chatroux, Louisa R. ; Savitsky, Leah M. ; Zwerling, Blake ; Williams, Justin ; Cahill, Alison G. ; Caughey, Aaron. / Standardizing the Response to Category II Tracings during Induction with Oxytocin : A Cost-Effectiveness Analysis. In: American Journal of Perinatology. 2017.
@article{76de51bdd40e49b7b917b298400bdb62,
title = "Standardizing the Response to Category II Tracings during Induction with Oxytocin: A Cost-Effectiveness Analysis",
abstract = "Background Oxytocin is one of the most frequently used medications in obstetrics. It is generally considered to be safe and effective for induction and augmentation of labor but has been implicated in uterine hyperstimulation and adverse fetal outcomes. The management of labor with oxytocin in response to changes in fetal status remains an area of debate. Objective This study sought to assess the cost-effectiveness of reducing or ceasing oxytocin administration in response to Category II fetal heart rate tracings. Study Design A decision-analytic model was built using TreeAge 2016 software (TreeAge Software Inc.) with probabilities, costs, and utilities derived from the literature. Primary outcomes included cerebral palsy (CP), neonatal mortality, and mode of delivery. Secondary outcomes included cost per quality-adjusted life year (QALY; cost-effectiveness threshold set at $100,000/QALY), admission to the neonatal intensive care unit (NICU), and low 5-minute Apgar score (<7). Sensitivity analyses were performed to determine the robustness of our baseline assumptions. Results In a theoretical cohort of 900,000 women (estimated number of women undergoing induction at term in the United States), decreasing or stopping oxytocin in response to Category II tracings prevented 12,510 NICU admissions, 4,410 low Apgar scores, 204 neonatal deaths, and 126 cases of CP. However, there were 81,900 more cesarean deliveries. The strategy cost $356 million more, but was cost-effective with an ICER of $9,881.5 per QALY. Sensitivity analysis revealed that the intervention would be cost-effective up to a cesarean rate of 54{\%}. Conclusion Decreasing or stopping oxytocin in response to Category II fetal heart rate tracings is cost-effective. This intervention increases the rate of cesarean deliveries but reduces neonatal morbidity and mortality. Further work on this guideline should be performed to ascertain how the approach using different aspects of the Category II tracing to guide care might lead to similar improved outcomes without increasing the cesarean delivery rate.",
keywords = "Category II tracing, cost-effectiveness, fetal heart rate monitoring, induction, labor management, oxytocin",
author = "Chatroux, {Louisa R.} and Savitsky, {Leah M.} and Blake Zwerling and Justin Williams and Cahill, {Alison G.} and Aaron Caughey",
year = "2017",
month = "8",
day = "16",
doi = "10.1055/s-0037-1606605",
language = "English (US)",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",

}

TY - JOUR

T1 - Standardizing the Response to Category II Tracings during Induction with Oxytocin

T2 - A Cost-Effectiveness Analysis

AU - Chatroux, Louisa R.

AU - Savitsky, Leah M.

AU - Zwerling, Blake

AU - Williams, Justin

AU - Cahill, Alison G.

AU - Caughey, Aaron

PY - 2017/8/16

Y1 - 2017/8/16

N2 - Background Oxytocin is one of the most frequently used medications in obstetrics. It is generally considered to be safe and effective for induction and augmentation of labor but has been implicated in uterine hyperstimulation and adverse fetal outcomes. The management of labor with oxytocin in response to changes in fetal status remains an area of debate. Objective This study sought to assess the cost-effectiveness of reducing or ceasing oxytocin administration in response to Category II fetal heart rate tracings. Study Design A decision-analytic model was built using TreeAge 2016 software (TreeAge Software Inc.) with probabilities, costs, and utilities derived from the literature. Primary outcomes included cerebral palsy (CP), neonatal mortality, and mode of delivery. Secondary outcomes included cost per quality-adjusted life year (QALY; cost-effectiveness threshold set at $100,000/QALY), admission to the neonatal intensive care unit (NICU), and low 5-minute Apgar score (<7). Sensitivity analyses were performed to determine the robustness of our baseline assumptions. Results In a theoretical cohort of 900,000 women (estimated number of women undergoing induction at term in the United States), decreasing or stopping oxytocin in response to Category II tracings prevented 12,510 NICU admissions, 4,410 low Apgar scores, 204 neonatal deaths, and 126 cases of CP. However, there were 81,900 more cesarean deliveries. The strategy cost $356 million more, but was cost-effective with an ICER of $9,881.5 per QALY. Sensitivity analysis revealed that the intervention would be cost-effective up to a cesarean rate of 54%. Conclusion Decreasing or stopping oxytocin in response to Category II fetal heart rate tracings is cost-effective. This intervention increases the rate of cesarean deliveries but reduces neonatal morbidity and mortality. Further work on this guideline should be performed to ascertain how the approach using different aspects of the Category II tracing to guide care might lead to similar improved outcomes without increasing the cesarean delivery rate.

AB - Background Oxytocin is one of the most frequently used medications in obstetrics. It is generally considered to be safe and effective for induction and augmentation of labor but has been implicated in uterine hyperstimulation and adverse fetal outcomes. The management of labor with oxytocin in response to changes in fetal status remains an area of debate. Objective This study sought to assess the cost-effectiveness of reducing or ceasing oxytocin administration in response to Category II fetal heart rate tracings. Study Design A decision-analytic model was built using TreeAge 2016 software (TreeAge Software Inc.) with probabilities, costs, and utilities derived from the literature. Primary outcomes included cerebral palsy (CP), neonatal mortality, and mode of delivery. Secondary outcomes included cost per quality-adjusted life year (QALY; cost-effectiveness threshold set at $100,000/QALY), admission to the neonatal intensive care unit (NICU), and low 5-minute Apgar score (<7). Sensitivity analyses were performed to determine the robustness of our baseline assumptions. Results In a theoretical cohort of 900,000 women (estimated number of women undergoing induction at term in the United States), decreasing or stopping oxytocin in response to Category II tracings prevented 12,510 NICU admissions, 4,410 low Apgar scores, 204 neonatal deaths, and 126 cases of CP. However, there were 81,900 more cesarean deliveries. The strategy cost $356 million more, but was cost-effective with an ICER of $9,881.5 per QALY. Sensitivity analysis revealed that the intervention would be cost-effective up to a cesarean rate of 54%. Conclusion Decreasing or stopping oxytocin in response to Category II fetal heart rate tracings is cost-effective. This intervention increases the rate of cesarean deliveries but reduces neonatal morbidity and mortality. Further work on this guideline should be performed to ascertain how the approach using different aspects of the Category II tracing to guide care might lead to similar improved outcomes without increasing the cesarean delivery rate.

KW - Category II tracing

KW - cost-effectiveness

KW - fetal heart rate monitoring

KW - induction

KW - labor management

KW - oxytocin

UR - http://www.scopus.com/inward/record.url?scp=85029762127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029762127&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1606605

DO - 10.1055/s-0037-1606605

M3 - Article

C2 - 28905354

AN - SCOPUS:85029762127

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

ER -